Tiziana Life Sciences announced that a late-breaking poster on its Phase 2a study of intranasal foralumab in Multiple System Atrophy has been accepted for presentation at the 7th World Parkinson Congress in May 2026.
Key takeaways
A late-breaking poster on the Phase 2a study of intranasal foralumab in Multiple System Atrophy (MSA) has been accepted for presentation at the 7th World Parkinson Congress in May 2026.
The poster will highlight the design and rationale of the ongoing TILS-025 trial, the first clinical investigation of intranasal anti-CD3 therapy in MSA.
The Phase 2a, open-label trial is enrolling up to 10 subjects with MSA in collaboration with Mass General Brigham MyTrial-MSA and Harvard Biomarkers Study 2.0 programs.
Primary endpoints include changes in microglial activation measured by PET imaging and changes in MDS-UMSARS scores.
Foralumab is the only fully human anti-CD3 monoclonal antibody currently in clinical development, with studies also ongoing in multiple sclerosis.